Xuebin Qu

Dr. Xuebin Qu


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 August 2021 in Cellular & Molecular Immunology
Verified
Journal Article
Closed access
PDF file
JHJingjing Han
Jingjing Han
WZWei Zhuang
Wei Zhuang
WFWanhua Feng
Wanhua Feng
FDFuxing Dong
Fuxing Dong
FHFang Hua
Fang Hua
XQXuebin Qu
Xuebin Qu

8 May 2019 in Journal of Neuroimmune Pharmacology
Verified
Journal Article
Closed access
PDF file
YZYing Zhang
Ying Zhang
JHJingjing Han
Jingjing Han
MWMeili Wu
Meili Wu
LXLu Xu
Lu Xu
YWYu Wang
Yu Wang
RYRuiqin Yao
Ruiqin Yao

27 September 2019 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
XQXuebin Qu
Xuebin Qu
JHJingjing Han
Jingjing Han
YZYing Zhang
Ying Zhang
XWXingqi Wang
Xingqi Wang
HFHongbin Fan
Hongbin Fan
RYRuiqin Yao
Ruiqin Yao
Background: Toll-like receptor 4 (TLR4) is well known for activating the innate immune system; however, it is also highly expressed in adaptive immune cells, such as CD4+ T-helper 17 (Th17) cells, which play a key role in multiple sclerosis (MS) pathology. However, the function and governing mechanism of TLR4 in Th17 remain unclear. Methods: The changes of TLR4 in CD4+ T cells from MS patients and experimental autoimmune encephalomyelitis (EAE) mice were tested. TLR4-deficient (TLR4−/−) naïve T cells were induced in vitro and transferred into Rag1−/− mice to measure Th17 differentiation and EAE pathology. DNA sequence analyses combining with deletion fragments and mutation analyses, chromatin immunoprecipitation (ChIP), and electrophoretic mobility shift assay (EMSA) were used to explore the mechanism of TLR4 signaling pathway in regulating Th17 differentiation. Results: The levels of TLR4 were increased in CD4+ Th17 cells both from MS patients and EAE mice, as well as during Th17 differentiation in vitro. TLR4−/− CD4+ naïve T cells inhibited their differentiation into Th17, and transfer of TLR4−/− CD4+ naïve T cells into Rag1−/− mice was defective in promoting EAE, characterized by less demyelination and Th17 infiltration in the spinal cord. TLR4 signal enhanced Th17 differentiation by activating RelA, downregulating the expression of miR-30a, a negative regulator of Th17 differentiation. Inhibition of RelA activity increased miR-30a level, but decreased Th17 differentiation rate. Furthermore, RelA directly regulated the expression of miR-30a via specific binding to a conserved element of miR-30a gene. Conclusions: TLR4−/− CD4+ naïve T cells are inadequate in differentiating to Th17 cells both in vitro and in vivo. TLR4-RelA-miR-30a signal pathway regulates Th17 differentiation via direct binding of RelA to the regulatory element of miR-30a gene. Our results indicate modulating TLR4-RelA-miR-30a signal in Th17 may be a therapeutic target for Th17-mediated neurodegeneration in neuroinflammatory diseases.

1 November 2019 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
PDF file
JHJingjing Han
Jingjing Han
YLYaping Liu
Yaping Liu
FZFei Zhen
Fei Zhen
WYWen Yuan
Wen Yuan
WZWei Zhang
Wei Zhang
XQXuebin Qu
Xuebin Qu
MicroRNAs are powerful regulators of gene expression in physiological and pathological conditions. We previously showed that the dysregulation of miR-384 resulted in a T helper cell 17 (Th17) imbalance and contributed to the pathogenesis of experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis. In this study, we evaluated the molecular mechanisms underlying the abnormal increase in miR-384. We did not detect typical CpG islands in the Mir384 promoter. Based on a bioinformatics analysis of the promoter, we identified three conserved transcription factor binding regions (RI, RII, and RIII), two of which (RII and RIII) were cis-regulatory elements. Furthermore, we showed that signal transducer and activator of transcription 3 (STAT3) bound to specific sites in RII and RIII based on chromatin immunoprecipitation, electrophoretic mobility shift assays, and site-specific mutagenesis. During Th17 polarization in vitro, STAT3 activation up-regulated miR-384, while a STAT3 phosphorylation inhibitor decreased miR-384 levels and reduced the percentage of IL-17+ cells, IL-17 secretion, and expression of the Th17 lineage marker Rorγt. Moreover, the simultaneous inhibition of STAT3 and miR-384 could further block Th17 polarization. These results indicate that STAT3, rather than DNA methylation, contributes to the regulation of miR-384 during Th17 polarization.